Pharmaceutical inventions have been the subject of special provisions in the past, the likes of which have not been applied to other inventions. Furthermore, pharmaceuticals are the subject of much government regulation outside of the patent system.
- Filter by
- Categories
- Tags
- Show all
- Article
- Confusion
- Contract
- Copyright
- Corporate
- Domain Names
- Employment
- Expungement
- Expungement
- Grey Marketing
- Industrial Designs
- Licensing
- Obviousness
- Opposition
- Passing Off
- Patent
- Patent Infringement
- Patent Strategy
- PCK News
- PM(NOC)
- Procedure
- Prosecution
- Services
- Summary
- Trade Secrets
- Trademark
- Use
- Validity
- Abandonment
- Abstract Theorems
- Abuse of Process
- Accounting of Profits
- Alice/Mayo Test
- Ambiguity
- Anticipation
- Appeal
- Apple
- Artificial Intelligence
- Assignment
- Bargain Theory
- Biosimilar
- Biotech Patents
- Branding
- business
- CAFC
- Canada
- Certificate of Supplementary Protection
- Chemical Patent
- CIPO
- claim
- Claim Construction
- Class Actions
- College of Patent Agents and Trademark Agents
- combination drugs
- Commercial Success
- Common General Knowledge
- Confidential Information
- Confusion
- Contract
- Copyright
- Copyright Infringement
- Costs
- Counterfeit
- Court of Appeals for the Federal Circuit
- COVID-19
- Damages
- Data Protection
- Design Patents
- Distinctiveness
- Diversity
- DNA Patents
- Domain Names
- Dosage Range
- Double Patenting
- Due Care
- E-Commerce
- Enablement
- Estoppel
- Evidence
- Expert Evidence
- Fair Use
- Federal Court
- Federal Court of Appeal
- File Wrapper Estoppel
- Food and Drug Regulations
- Fraud
- funding
- Generic Drugs
- Hague Agreement
- Indefiniteness
- Induced Infringement
- Industrial Designs
- Injunction
- Innovation
- Innovative Drugs
- Insufficient Disclosure
- Intellectual Property
- Inter Partes Review
- Investors
- IP Litigation
- IP Strategy
- IP Treaty
- IPIC
- Jurisdiction
- Law Firm
- Licensing IP
- Madrid Protocol
- Methods of Medical Treatment
- Non-Infringing Alternative
- Non-Practicing Entity
- Novelty
- Obviousness
- Official Marks
- On-Sale Bar
- Overbreadth
- Ownership & Inventorship
- Passing Off
- Patent Act
- Patent Agent
- Patent Appeal Board
- Patent Application
- Patent Drafting
- Patent Fees
- Patent Infringement
- Patent Law
- Patent Lawyer
- Patent Litigation
- Patent Prosecution
- Patent Rules
- Patent Strategy
- Patent Term Adjustment
- Patent Textbook
- Patent Trolls
- Patent Validity
- Patentable Subject Matter
- Patents
- PCT
- Pharmaceutical Patent
- Pharmaceutical Pricing
- PM(NOC)
- PMPRB
- Prior Art
- Prior Disclosure
- prior use
- Priority
- Privilege
- Product Specificity
- Promise Doctrine
- Provisional Patent
- Punitive Damages
- Reinstatement
- Remedies
- SCOTUS
- Selection Patent
- Software
- Software Copyright
- Software Patent
- Sound Prediction
- Springboard Profits
- SRED
- Standard of Review
- Start-up
- Startups
- Supreme Court of Canada
- Technology
- Trade Secrets
- Trademark
- Trademark Agent
- Trademark Expungement
- Trademark Infringement
- Trademark Law
- Trademark Opposition
- Trademark Registration
- Trademarks Act
- United States
- Use
- USPTO
- Utility
January 27, 2014
January 27, 2014
Pfizer Ireland Pharmaceuticals v Apotex Inc. [2014 FCA 13] Background This is an appeal of the summary judgment decision of Justice Zinn where he declared a […]
January 23, 2014
January 23, 2014
AbbVie Corporation v Janssen Inc. [2014 FC 55] Background The action is in respect of a patent directed to human antibodies capable of binding a […]
January 7, 2014
January 7, 2014
Alcon Canada Inc. v Apotex Inc. [2012 FC 410] Background The patent at issue is Canadian Patent 2,195,094. The patent is for a topical ophthalmic […]
January 7, 2014
January 7, 2014
Gilead Sciences Inc. v Canada (Health) [2013 FC 1270] Bristol-Myers Squibb v Canada(Health) [2013 FC 1271] Gilead Sciences Inc. v Canada(Health) [2013 FC 1272] Background […]
December 23, 2013
December 23, 2013
Re. Application 2,365,923 CD 1343 Background The Application is for a patent for the use of a drug to treat patients suffering from a rare genetic […]
December 23, 2013
December 23, 2013
Apotex Inc. v Takeda Canada Inc. 2013 FC 1237 Background This is an application under section 8 of the PM(NOC) process dealing with lost revenue […]
November 28, 2013
November 28, 2013
Apotex Inc. v. H. Lundbeck A/S [2013 FC 1188] Background Apotex was the losing party in an impeachment trial of Lundbeck’s Canadian Patent 1,339,452 in which Lundbeck […]
October 29, 2013
October 29, 2013
Bayer Inc. v Cobalt Pharmaceuticals Company [2013 FC 1061] Background This proceeding is an application under the NOC regulations by Bayer seeking a prohibition order to […]
October 24, 2013
October 24, 2013
Mylan Pharmaceuticals ULC v Bristol-Myers Squibb Canada Co. [2013 FCA 231] Background This is an appeal of a cost award from a Judgment of Justice Barnes […]
October 18, 2013
October 18, 2013
F Hoffmann-La Roche AG v Commissioner of Patents, 2013 FC 1001. Background This is an application for an order pursuant to s. 20 of the […]
October 8, 2013
October 8, 2013
Novartis Pharmaceuticals Canada Inc. v Cobalt Pharmaceuticals Company [2013 FC 985] Affirmed on Appeal [2014 FCA 17] Background This is an application under the NOC regulations […]
September 16, 2013
September 16, 2013
Apotex Inc. v Abbot Laboratories Ltd. Takeda Pharmaceuticals Company Ltd. And Takeda Pharmaceuticals America Inc. 2013 ONCA 555 Apotex appealed the dismissal of its unjust […]
July 29, 2013
July 29, 2013
Sanofi-Aventis v. Apotex Inc. – 2013 FCA 186 Per Pelletier J.A. (Noel J.A. concurring): Apotex attempted to market a generic version of clopidogrel bisulfate (clopidogrel), sold […]
July 24, 2013
July 24, 2013
Hoffman-La Roche Limited v. Apotex Inc., 2013 FC 718 In this application brought under the PM(NOC) Regulations Roche sought to prohibit the Minister of Health from […]
July 3, 2013
July 3, 2013
Wyeth v. Abbot Labs (Fed. Cir. 2013) Wyeth appealed from the U.S. District Court for the District of New Jersey’s grant of summary judgment that claims […]
June 13, 2013
June 13, 2013
Effective June 10, 2013 PN2013-04 This Practice Notice builds upon the guidance in section 17.02.03 (Medical and surgical methods) of MOPOP and in PN 2013-02 (Examination […]
June 13, 2013
June 13, 2013
Teva Canada Limited v. Pfizer Canada Inc. (33951) The Supreme Court has revised its Sildenafil (Viagra) decision (2012 SC 60). The Court granted, in part, Pfizer’s […]
June 7, 2013
June 7, 2013
Bayer Inc. v. Cobalt Pharmaceuticals, 2013 FC 573 Bayer sought an order prohibiting the Minister of Health from issuing a Notice of Compliance (NOC) to Cobalt, […]
May 29, 2013
May 29, 2013
Apotex Inc. v Pfizer Canada Inc. – 2013 FC 493 Apotex claimed damages under s. 8 of the PM(NOC) Regulations on grounds that it incurred a […]
May 3, 2013
May 3, 2013
Teva Canada Innovation v. Canada (Attorney General), 2013 FC 448 Teva asked the Court to set aside a decision of the Patented Medicine Prices Review Board […]